1-2 of 2
Jeffrey Jones
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

Shanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, Lindsey Rike, Xiaokui Mo, Mohamed Badawi, Darlene M. Bystry, Mitch A. Phelps, Leslie A. Andritsos, Kerry A. Rogers, Jeffrey Jones, Jennifer A. Woyach, John C. Byrd, Farrukh T. Awan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6187–6195.
https://doi.org/10.1158/1078-0432.CCR-20-1280
Published: 01 December 2020
View article titled, Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
Open the PDF for Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O'Brien
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1149–1155.
https://doi.org/10.1158/1078-0432.CCR-16-1431
Published: 28 February 2017
View article titled, Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Open the PDF for Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in another window
Includes: Supplementary data